Nabriva Therapeutics AG - Company Profile (NASDAQ:NBRV)

About Nabriva Therapeutics AG -

Nabriva Therapeutics AG - logoNabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NBRV
  • CUSIP:
Key Metrics:
  • Previous Close: $7.33
  • 50 Day Moving Average: $7.5837
  • 200 Day Moving Average: $8.0424
  • 52-Week Range: $21,257,000.00 - $6.61
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.70
  • P/E Growth: 0.0000
  • Market Cap: $155.80M
  • Outstanding Shares: 21,257,000
Additional Links:
Companies Related to Nabriva Therapeutics AG -:

Analyst Ratings

Consensus Ratings for Nabriva Therapeutics AG - (NASDAQ:NBRV) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.17 (134.22% upside)

Analysts' Ratings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2016HC WainwrightInitiated CoverageBuy$16.00View Rating Details
8/9/2016WedbushReiterated RatingOutperform$17.00View Rating Details
1/27/2016GabelliInitiated CoverageBuy$14.00View Rating Details
11/12/2015Needham & Company LLCReiterated RatingBuy$15.00View Rating Details
11/12/2015Royal Bank Of CanadaBoost Price TargetOutperform$21.00 -> $22.00View Rating Details
10/13/2015Leerink SwannInitiated CoverageOutperform$10.00 -> $19.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/9/2016($6.25)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Current Year EPS Consensus Estimate: $-1.9300 EPS
Next Year EPS Consensus Estimate: $-2.7100 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.58)($0.58)($0.58)
Q3 20161($0.50)($0.50)($0.50)
Q4 20161($0.10)($0.10)($0.10)
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Nabriva Therapeutics AG - (NASDAQ:NBRV)
DateHeadline
finance.yahoo.com logoNabriva to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:NBRV)
finance.yahoo.com - September 6 at 11:03 AM
finance.yahoo.com logoShould Nabriva Therapeutics (NBRV) Be On Your Radar Now? (NASDAQ:NBRV)
finance.yahoo.com - September 6 at 11:03 AM
finance.yahoo.com logoNabriva to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:NBRV)
finance.yahoo.com - August 10 at 9:29 AM
publicnow.com logoNabriva Reports Second Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - August 9 at 9:35 AM
publicnow.com logoNabriva Announces Nomination of Candidates for Its Supervisory Board (NASDAQ:NBRV)
www.publicnow.com - July 25 at 7:28 AM
fxpips.com logoMost Advanced Stocks on NASDAQ (NASDAQ:NBRV)
www.fxpips.com - July 20 at 9:18 AM
finance.yahoo.com logoF2G Ltd Announces the Appointment of Ralf Schmid to the Position of Chief Financial Officer (NASDAQ:NBRV)
finance.yahoo.com - July 11 at 4:00 AM
publicnow.com logoNabriva to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - July 5 at 7:21 AM
nasdaq.com logoEuropean ADRs Marginally Higher as Healthcare Stocks See Mixed Fortunes (NASDAQ:NBRV)
www.nasdaq.com - July 1 at 6:23 PM
nasdaq.com logoNabriva Presents Data on Lefamulin at the American Society of Microbiology (ASM) Microbe 2016 Conference (NASDAQ:NBRV)
www.nasdaq.com - June 20 at 6:16 PM
publicnow.com logoNabriva to Present at the JMP Securities Life Sciences Conference (NASDAQ:NBRV)
www.publicnow.com - June 14 at 7:19 AM
capitalcube.com logoNabriva Therapeutics AG :NBRV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 (NASDAQ:NBRV)
www.capitalcube.com - June 6 at 2:31 PM
marketwatch.com logoNabriva Therapeutics AG (US: NBRV) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:NBRV)
www.marketwatch.com - June 1 at 6:52 PM
publicnow.com logoNabriva Therapeutics AG (Nasdaq: NBRV) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:NBRV)
www.publicnow.com - May 31 at 10:22 AM
publicnow.com logoNabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference (NASDAQ:NBRV)
www.publicnow.com - May 16 at 7:32 AM
publicnow.com logoNabriva to Present at the UBS Global Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - May 11 at 7:22 AM
publicnow.com logoNabriva Reports First Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - May 10 at 7:18 AM
finance.yahoo.com logoNABRIVA THERAPEUTICS AG Financials (NASDAQ:NBRV)
finance.yahoo.com - May 5 at 1:04 PM
publicnow.com logoNabriva Appoints Gary Sender as Chief Financial Officer (NASDAQ:NBRV)
www.publicnow.com - May 2 at 7:10 AM
finance.yahoo.com logo7:00 am Nabriva Therapeutics appoints Gary Sender as CFO, effective immediately (NASDAQ:NBRV)
finance.yahoo.com - May 2 at 7:00 AM
biz.yahoo.com logoNabriva Therapeutics AG Earnings Call scheduled for 8:30 am ET today (NASDAQ:NBRV)
biz.yahoo.com - April 27 at 8:30 AM
publicnow.com logoNabriva Therapeutics AG Reports Full Year 2015 Financial Results and Provides Development Update (NASDAQ:NBRV)
www.publicnow.com - April 27 at 7:21 AM
biz.yahoo.com logoQ4 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open (NASDAQ:NBRV)
biz.yahoo.com - April 27 at 7:07 AM
publicnow.com logoNabriva Therapeutics AG to Provide Development Update and Announce Full Year 2015 Financial Results; Conference Call on Wednesday, April 27, 2016 (NASDAQ:NBRV)
www.publicnow.com - April 19 at 7:15 AM
marketexclusive.com logoNabriva Therapeutics (NASDAQ:NBRV) Initiates 2nd Phase III Trials of Lefamulin (NASDAQ:NBRV)
marketexclusive.com - April 15 at 12:10 PM
publicnow.com logoNabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia (CABP) (NASDAQ:NBRV)
www.publicnow.com - April 11 at 8:20 AM
publicnow.com logoNabriva Therapeutics AG to Present at the 15th Annual Needham Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - April 5 at 7:17 AM
bilbaoya.com logoAverage Rating Watch Nabriva Therapeutics AG - ADR (NASDAQ:NBRV) (NASDAQ:NBRV)
bilbaoya.com - March 31 at 10:53 AM
wsj.com logo[$$] Iterum Therapeutics Secures $40M Series A, Licenses Anti-Infective Drug (NASDAQ:NBRV)
www.wsj.com - March 28 at 9:07 AM
finance.yahoo.com logoNabriva Therapeutics AG to Participate in Two Investor Conferences in February (NASDAQ:NBRV)
finance.yahoo.com - February 3 at 7:00 AM
finance.yahoo.com logoCoverage initiated on Nabriva Therapeutics by Gabelli & Co (NASDAQ:NBRV)
finance.yahoo.com - January 27 at 9:07 AM
finance.yahoo.com logoNabriva Therapeutics AG (NBRV) (NASDAQ:NBRV)
finance.yahoo.com - January 21 at 8:56 AM
insidermonkey.com logoDo Hedge Funds Love Lawson Products, Inc. (LAWS)? (NASDAQ:NBRV)
www.insidermonkey.com - November 27 at 9:42 AM
noodls.com logoNabriva Therapeutics AG Provides Development Update and Reports Nine Month 2015 Financial Results (NASDAQ:NBRV)
www.noodls.com - November 11 at 7:26 AM
biz.yahoo.com logoQ3 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open (NASDAQ:NBRV)
biz.yahoo.com - November 11 at 7:07 AM
noodls.com logoNabriva Therapeutics AG to Provide Development Update and Announce Nine Month 2015 Financial Results; Conference Call on Wednesday, November 11, 2015 (NASDAQ:NBRV)
www.noodls.com - November 4 at 7:27 AM
insidermonkey.com logoThese Two Healthcare Stocks Receive A Vote Of Confidence From Elite Hedge Fund Managers (NASDAQ:NBRV)
www.insidermonkey.com - October 5 at 12:57 PM
noodls.com logoNabriva Therapeutics Announces Closing of Its Initial Public Offering (NASDAQ:NBRV)
www.noodls.com - September 23 at 4:35 PM
noodls.com logoNabriva Therapeutics Prices Initial Public Offering (NASDAQ:NBRV)
www.noodls.com - September 21 at 2:05 PM
noodls.com logoInitial Public Offering of Nabriva Therapeutics (NASDAQ:NBRV)
www.noodls.com - September 21 at 12:35 AM
247wallst.com logoIPO Calendar Shows 3 Offerings on Tap for the Coming Week (NASDAQ:NBRV)
247wallst.com - September 20 at 9:38 AM
investors.com logoIPO Stock Watch: Regenxbio Jumps On First Trading Day (NASDAQ:NBRV)
news.investors.com - September 17 at 4:20 PM
investors.com logoRegenxbio Turns In Strong, Upsized IPO Performance (NASDAQ:NBRV)
news.investors.com - September 16 at 6:22 PM

Social

Nabriva Therapeutics AG - (NASDAQ:NBRV) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff